EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

In Suspected Fetal Growth Restriction, sFlt ‐1/ PlGF and PlGF May Have Value in Risk Stratification for Preterm Birth and Birthweight < 3rd Centile: A Blinded Cohort Study

Ruth C E Hughes iD, Pippa Kyle, Ian Phillips, Chris M Florkowski, Joanna Gullam

Australian and New Zealand Journal of Obstetrics and Gynaecology · 2025

DOI: 10.1111/ajo.70003 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Australian and New Zealand Journal of Obstetrics and Gynaecology, 2025. Verfasst von Ruth C E Hughes und 4 weiteren Autor:innen. Beteiligte Einrichtung: Christchurch Women's Hospital, Te Whatu Ora - Waitaha Canterbury, Christchurch, New Zealand. Hauptthemen laut MEDLINE: Fetal Growth Retardation, Vascular Endothelial Growth Factor Receptor-1, Premature Birth, Placenta Growth Factor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We investigated the value of measuring sFlt‐1/PlGF in people with suspected fetal growth restriction (sFGR) without signs of preeclampsia at recruitment. Angiogenic biomarkers were considered positive when sFlt‐1/PlGF > 38 or PlGF < 100 pg/mL. Clinicians were blinded to the sFlt‐1/PlGF results. In sFGR presenting < 32 weeks, but not ≥ 32–37 weeks, positive angiogenic biomarkers vs. NZ FGR criteria had increased risk of preterm birth RR 5.32 [2.04–13.88] vs. 2.19 [0.89–5.37], respectively, and birthweight < 3rd centile RR 2.11 [1.24–3.58] vs. 1.83 [0.92–3.63], respectively. Larger studies are needed to establish whether routine testing of angiogenic biomarkers in sFGR is recommended for risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fetal Growth RetardationVascular Endothelial Growth Factor Receptor-1Premature BirthPlacenta Growth FactorBirth WeightHumansFemalePregnancyBiomarkersAdultInfant, NewbornRisk AssessmentCohort StudiesGestational Age

Stichwörter der Autor:innen

fetal growth restrictionplacental growth factorplacental insufficiencysmall for gestational agevascular endothelial growth factor receptor‐1

Substanzen

Vascular Endothelial Growth Factor Receptor-1FLT1 protein, humanBiomarkersPlacenta Growth FactorPGF protein, human

Autor:innen und Institutionen

  • Christchurch Women's Hospital, Te Whatu Ora - Waitaha Canterbury, Christchurch, New Zealand.
  • Department of Obstetrics and Gynaecology, University of Otago, Christchurch, New Zealand.
  • Canterbury Health Laboratories, Christchurch, New Zealand.
  • Awanui Laboratories, Dunedin, New Zealand.

ORCID-Profile: Ruth C E Hughes

Zitieren

APA

Hughes, R. C. E., Kyle, P., Phillips, I., Florkowski, C. M., & Gullam, J. (2025). In Suspected Fetal Growth Restriction, sFlt ‐1/ PlGF and PlGF May Have Value in Risk Stratification for Preterm Birth and Birthweight < 3rd Centile: A Blinded Cohort Study. Australian and New Zealand Journal of Obstetrics and Gynaecology. https://doi.org/10.1111/ajo.70003

Vancouver

Hughes RCE, Kyle P, Phillips I, Florkowski CM, Gullam J. In Suspected Fetal Growth Restriction, sFlt ‐1/ PlGF and PlGF May Have Value in Risk Stratification for Preterm Birth and Birthweight < 3rd Centile: A Blinded Cohort Study. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2025. doi:10.1111/ajo.70003

BibTeX
@article{Hughes2025,
  author = {Hughes, Ruth C E and Kyle, Pippa and Phillips, Ian and Florkowski, Chris M and Gullam, Joanna},
  title = {In Suspected Fetal Growth Restriction, sFlt ‐1/ PlGF and PlGF May Have Value in Risk Stratification for Preterm Birth and Birthweight < 3rd Centile: A Blinded Cohort Study},
  journal = {Australian and New Zealand Journal of Obstetrics and Gynaecology},
  year = {2025},
  doi = {10.1111/ajo.70003}
}
Kostenlos starten →